ArticleOPEN ACCESS

Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial

Annals of Oncology
DOI: 10.1093/annonc/mdw298
3Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We described our concerns about the possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with Advanced Non-Small-Cell Lung Cancer enrolled in ARCHER-1042 trial

Cite

CITATION STYLE

APA

Ceccarelli, G., Schietroma, I., Corano Scheri, G., d’Ettorre, G., & Vullo, V. (2016, November 1). Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial. Annals of Oncology. Elsevier Ltd. https://doi.org/10.1093/annonc/mdw298

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free